Item 1.
|
SECURITY AND ISSUER
|
The name of the issuer is Navidea Biopharmaceuticals, Inc., a Delaware corporation (the Issuer). The address of the Issuers principal
executive offices is 4995 Bradenton Avenue, Suite 240, Dublin, Ohio 43017-3552. This Schedule 13D relates to the Issuers common stock, par value $0.001 per share (the Common Stock).
Item 2.
|
IDENTITY AND BACKGROUND
|
(a) This Amendment No. 1 to Schedule 13D is being filed by John K. Scott, Jr. (the Reporting Person), a natural person.
(b) The Reporting Persons business address is 5251 DTC Parkway, Suite 285, Greenwood Village, CO 80111.
(c) The Reporting Persons principal occupation is a self-employed investor. The Reporting Persons business address is 5251 DTC Parkway, Suite 285,
Greenwood Village, CO 80111.
(d) The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors).
(e) The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.
(f) The Reporting Person is a citizen of the United States.
Item 3.
|
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
|
Effective April 26, 2019, the Issuer effected a 1-for-20 reverse stock
split of its outstanding Common Stock. Where applicable, Common Stock share amounts described below have been adjusted to give effect to the 1-for-20 reverse stock
split, with fractional shares rounded down to the nearest whole share.
On September 17, 2018, the Reporting Person purchased 916,030 shares of
Common Stock for an aggregate purchase price of $3,000,000 from the Issuer in a private placement pursuant to a Stock Purchase Agreement, dated September 13, 2018, by and between the Issuer and the Reporting Person (the September Purchase
Agreement). Prior to the closing of the transactions contemplated by the September Purchase Agreement, the Reporting Person had acquired 179,190 shares of Common Stock in open market purchases. The aggregate purchase price for such 179,190
shares was approximately $1,300,000.
On March 22, 2019, the Reporting Person purchased 17,857 shares of Common Stock for an aggregate purchase price
of $50,000 from the Issuer in a private placement pursuant to a Stock Purchase Agreement, dated March 22, 2019, by and between the Issuer and the Reporting Person (the March Purchase Agreement). While the March Purchase Agreement
contemplated subsequent closings at which the Reporting Person would acquire additional shares of Common Stock, no such subsequent closings occurred, and no additional shares of Common Stock were acquired pursuant to the March Purchase Agreement.
On June 13, 2019, the Issuer entered into an underwriting agreement relating to an underwritten public offering of 8,000,000 shares of Common Stock.
The Reporting Person purchased 4,000,000 shares of Common Stock from the underwriter in the underwritten public offering for an aggregate purchase price of $3,000,000. The closing of such purchase occurred on June 18, 2019.
On December 6, 2019, the Reporting Person subscribed for 555,555 shares of Common Stock for an aggregate purchase price of $500,000 from the Issuer in a
private placement pursuant to a Stock Purchase Agreement, dated December 6, 2019, by and between the Issuer and the Reporting Person (the December Purchase Agreement).
The funds used for the purchase of 179,190 shares of Common Stock in the open market and for the subscription for 555,555 shares of Common Stock pursuant to
the December Purchase Agreement were derived from personal funds of the Reporting Person. The funds used for the purchase of the remaining shares of Common Stock reported in this Item 3 of this Schedule 13D were derived from a revolving line of
credit (the Revolving Line of Credit) entered into by and between the Reporting Person and Phelps Tointon, Inc. that has been in effect since June 4, 2010 and from which the Reporting Person draws for the Reporting Persons
general investments. Contact information for Phelps Tointon, Inc. is PO Box 9, Greeley, Colorado, 80632, Attn: Travis Gillmore, Tel: (970) 353-7000.
3